{"id":"nct:NCT03838575","kind":"trial","title":"ROSSINI 2 - Reduction of Surgical Site Infection Using Several Novel Interventions","authors":["University of Birmingham"],"author_count":1,"year":2019,"published":"2019-02-12","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT03838575","source_url":"https://clinicaltrials.gov/study/NCT03838575","archive_url":"https://space-kitty.com/papers/nct:NCT03838575","updated":"2022-11-28","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"ROSSINI 2 is a phase III, multi-arm, multi-stage (MAMS) pragmatic, blinded (patient and outcome assessor), multicentre, randomised controlled trial (RCT) with an internal pilot, to evaluate the use of several in-theatre interventions, used alone or in combination, to reduce SSI rates in patients undergoing surgery.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["Surgical Site Infection","Surgical Wound Infection","Surgery--Complications","Surgery"],"details":{"acronym":"ROSSINI 2","status":"UNKNOWN","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":6610,"sponsor":"University of Birmingham","conditions":["Surgical Site Infection","Surgical Wound Infection","Surgery--Complications","Surgery"],"interventions":["DRUG: 2% alcoholic chlorhexidine skin prep (SKIN PREP)","DEVICE: Iodophor Antimicrobial Incise Drapes (DRAPE)","DEVICE: Gentamicin-impregnated implants/ sponges (SPONGE)","OTHER: NONE (Control)"],"start_date":"2019-03-01","start_date_type":"ACTUAL","primary_completion_date":"2023-05-01","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"infectious-disease-amr","name":"Infectious Disease, Vaccines & Antimicrobial Resistance","domain_slug":"medicine"}],"cited_in_dossiers":[]}